Plasma Levels of Pentosidine, Carboxymethyl-Lysine, Soluble Receptor for Advanced Glycation End Products, and Metabolic Syndrome: The Metformin Effect

Table 4

Correlation between pentosidine, CML, sRAGE levels and drugs treatment in patients with MetS: linear regression analysis.

Variables	Pentosidine		CML		sRAGE
	Metformin treatment	−0.311	0.009	0.177	NS	0.401	<0.001
ACE inhibitors treatment	−0.054	NS	0.021	NS	0.352	0.002
Metformin + ACE inhibitors treatment	−0.071	NS	0.07	NS	0.408	<0.001